F S&P 500
5,125.25 +18.75 (+0.37%) F Dow Jones
38,781.00 +55.00 (+0.14%) F Nasdaq
17,734.75 +128.00 (+0.73%) E-mini Russell 2000 Index Futur
2,018.10 +3.20 (+0.16%) Petróleo
83.40 +0.04 (+0.05%) Oro
2,338.10 -4.00 (-0.17%)
Titan Pharmaceuticals, Inc. (TTNP)
Fuera de horario:
Titan Pharmaceuticals, Inc.
400 Oyster Point Boulevard
Suite 505
South San Francisco, CA 94080
United States
650 244 4990
https://www.titanpharm.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 4
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. David Elliot Lazar | CEO & Principal Financial Officer | 1.42M | N/D | 1991 |
| Dr. Katherine L. Beebe-DeVarney Ph.D. | President, COO & Director | 462k | N/D | 1961 |
| Mr. Mike Fritz | National Sales Director | N/D | N/D | N/D |
| Jennifer Kiernan | Executive Assistant to CEO & Investor Communications Coordinator | N/D | N/D | N/D |
| Joe Schrei | Executive Director of Commercial Operations | N/D | N/D | N/D |
Descripción
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Titan Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
